System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Consensus Statement Journal Article Review Ppublish

PubMed: 42810452 DOI: 10.1016/j.ijcard.2026.134944

Personalised antiplatelet therapy during elective percutaneous coronary intervention in patients with chronic coronary syndrome: An international journal of cardiology expert consensus statement.

Int J Cardiol 465:134944

Authors: Francesco Pelliccia, Giuseppe Andò, Piera Capranzano, Felice Gragnano, Giuseppe Patti, Italo Porto, Giulio Stefanini, Marco Zimarino, Paolo Calabrò

Affiliations

  • Department of Cardiovascular Sciences, University Sapienza, Rome, Italy.
  • Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
  • Division of Cardiology, Policlinico Hospital, University of Catania, S. Sofia, Catania, Italy.
  • Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Caserta, Italy; Division of Clinical Cardiology, A.O.R.N. "Sant'Anna e San Sebastiano", Caserta, Italy.
  • Department of Translational Medicine University of Eastern Piedmont, Novara, Italy; Maggiore della Carità Hospital Novara, Italy.
  • Department of Internal Medicine and Medical Specialties (DIMI) Università di Genova, Genoa, Italy; Cardiothoracic and Vascular Department (DICATOV), IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Humanitas Research Hospital IRCCS, Rozzano-, Milan, Italy.
  • Department of Cardiology, SS. Annunziata Hospital, ASL2 Abruzzo, Chieti, Italy; Department of Neuroscience, Imaging and Clinical Sciences, "Gabriele d'Annunzio" University of Chieti-Pescara, Chieti, Italy.

Abstract

Oral P2Y12 inhibitors represent the mainstay therapy for the prevention of thrombotic complications in patients undergoing percutaneous coronary intervention (PCI) and coronary stent implantation. However, the onset of antiplatelet action of the oral P2Y12 inhibitors is affected by their need to be absorbed in the gastrointestinal tract before becoming systemically available. Following oral intake of P2Y12 inhibitors, the timeframe required for gastrointestinal absorption leads to a periprocedural period of less consistent platelet inhibition at the time of PCI during which patients are potentially at increased risk of thrombotic events. In order to reduce periprocedural ischemic events in patients undergoing PCI, a more rapid platelet inhibition can be obtained with intravenous antiplatelet drugs. Glycoprotein IIb/IIIa receptor inhibitors are effective but their use is limited by bleeding concerns. Cangrelor is an intravenous, direct, and reversible P2Y12 receptor antagonist that provides rapid and predictable platelet inhibition with rapid offset after discontinuation, without a significant increase in major bleeding. In this expert consensus statement, we reviewed available evidence on antiplatelet treatment optimisation in patients undergoing elective PCI, highlighting the importance of a personalised approach.

MeSH

Stents, Hemorrhage, Percutaneous Coronary Intervention, Cardiology, Therapeutics, Blood Platelets